Liquid Biopsy Markets 2027–2031

Liquid Biopsy Markets: Market Forecast, Competitive Landscape, Technology and Partnering Opportunities, 2027–2031 (10th Edition, October 2026)

Global forecasts by cancer type, application, analyte, technology platform and product, for 14 countries and regions, with 90 company profiles.

See the Table of Contents. GET the Free Sample of this Report.

Many organizations subscribe to all or some of our reports. You may already have free access to this report. FIND out Here.

Our Take

Liquid biopsy is moving from choosing cancer drugs to finding cancer early and watching for its return. The market doubles from $8.5 billion in 2026 to $17.5 billion in 2031, growing 15.4% a year. Screening tests rise from 18% to 34% of the market and supply almost half of the new spending, and MRD testing adds $2.6 billion. Therapy selection remains the largest application but is maturing fast.

Market Size 2026: USD $8.5B   Market Size 2031: USD $17.5B   CAGR: 15.4%

Situation Analysis: what is really happening

• Screening is where the growth is. Single-cancer and multi-cancer screening rise from 18% to 34% of the market and supply 48% of the $9.0 billion of new spending. Two blood tests for colorectal screening are now FDA approved, and Medicare can cover approved multi-cancer early detection tests from 2029.
• MRD is the largest single source of growth. MRD and monitoring adds $2.6 billion to reach $4.8 billion in 2031. Signatera CDx became the first FDA-approved MRD companion diagnostic in May 2026.
• Therapy selection is maturing. It remains the largest application at $5.5 billion in 2031, but grows only 6.3% a year and falls from 48% to 31% of the market.
• The epigenomic shift. Tests that read methylation and fragment patterns grow 28% a year, from 16% to 27% of the market, reaching $4.7 billion.
• Central laboratories capture the value. Tests run in manufacturers' own laboratories rise from 62% to 68% of the market. Roche's plan for a hospital-run MRD test is the first serious challenge to that model.

Company Analysis: who is positioned, who is exposed

• Natera: The MRD leader with Signatera, now strengthened by Foresight's phased-variant technology and the first MRD companion diagnostic approval.
• Guardant Health: Spans therapy selection, MRD and screening, with the new Guardant360 Liquid CDx and the Shield colorectal screening test.
• GRAIL: Galleri won a favourable FDA panel vote, but the NHS-Galleri trial missed its primary endpoint, so timing of approval and Medicare coverage is the key risk.
• Abbott (Exact Sciences): Brings stool and blood screening, MRD and a multi-cancer test together under one of the largest diagnostics sales forces.
• Roche and Foundation Medicine: Buying SAGA to build an MRD test that hospital laboratories can run on Roche instruments.
• Tempus AI: Acquiring Personalis for about $1.5 billion to add whole-genome MRD to its data platform.

Plus 84 more company profiles, each one to two pages with a fact box covering website, headquarters, ownership, revenue, employees and key products.

Questions this report answers

• How fast will blood-based screening grow, and when will Medicare pay for multi-cancer tests?
• How large can MRD testing become now that it guides treatment as well as prognosis?
• Which analytes and technologies will win: mutations, methylation, fragments, CTCs or vesicles?
• Will central laboratories keep their hold on the market, or will testing move to hospital laboratories?
• What are MRD and screening companies selling for, and who is buying?
• How large is each country market, and how fast is China growing?

What's inside

• 407 pages, 24 chapters, 51 tables and 59 figures
• Forecasts for 2027–2031 from a 2026 base year, by cancer type, application, analyte, technology platform and product, for 14 countries and regions
• Approved and launched test landscape, clinical evidence and pipeline, companion diagnostics and pharma partnerships
• Regulation and reimbursement, intellectual property and pricing, a China chapter and a deal database
• 10 market-moving developments from 2025 and 2026, SWOT, Porter's Five Forces and strategic recommendations
• 90 company profiles
• Download the Table of Contents (PDF)

Who buys this report

• Diagnostics executives and business development teams: size screening and MRD opportunities and find partners and acquisition targets.
• Pharma companion diagnostic teams: choose liquid biopsy partners and plan ctDNA endpoints in trials.
• Investors and analysts: model the growth of screening and MRD and benchmark deal values.
• Laboratory and instrument suppliers: judge demand for sequencing, PCR and kits in central and hospital laboratories.

Use independent research that makes you the expert. Your credit card order sends the report to your inbox instantly. Check all your licensing options, but don't worry: your order is available as a credit if you wish to upgrade.

See the Table of Contents. GET the Free Sample of this Report.

ABOUT THE LEAD AUTHOR

Mr. Greg Powell, B.Sc., M.B.A., is the President of Howe Sound Research. His education includes:

Finance for Senior Executives - Harvard Business School

Market Research - Burke Institute

M.B.A. (Finance and Policy) - University of British Columbia

B.Sc. (Chemistry) - University of British Columbia

He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years.